Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an announcement.
Hangzhou Tigermed Consulting Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, which will take place on May 30, 2025. The meeting will address several key resolutions, including the approval of the 2024 Annual Report, financial statements, profit distribution plan, and the appointment of an auditor for 2025. Additionally, the meeting will consider changes in the use of proceeds from the H Shares offering, remuneration standards for directors and supervisors, and amendments to the Articles of Association. These resolutions are pivotal for the company’s strategic direction and governance, potentially impacting its financial management and shareholder relations.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the consulting industry. The company primarily focuses on providing clinical trial services and solutions to the pharmaceutical and biotechnology sectors.
YTD Price Performance: -19.13%
Average Trading Volume: 121
Technical Sentiment Signal: Buy
Current Market Cap: €3.88B
See more insights into 3347 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue